



PRESS RELEASE

September 1, 2022

Ziccum on the move: company to attend major industry events across Europe in 2022

Ziccum AB will be intensifying its partnering and networking dialogues at a series of leading pharma industry events throughout Europe this year. CEO Ann Gidner: "As we strengthen our connections with colleagues throughout the industry, we remain confident in the unique advantages that ambient drying and thermostable vaccines represent. It's going to be an exciting season."

CEO Ann Gidner and Chairman Fredrik Sjövall will attend Nordic Life Sciences Days in Malmö, 28 – 29 September, and Bio-Europe, the largest industry event for biopharma professionals in Europe, in Leipzig on 23 – 26 October.

The company's CEO together with Scientific Director Fabrice Rose will attend the New Updates in Drug Formulation & Bioavailability conference in Copenhagen on September 6, and the 23rd World Vaccine Congress Europe conference in Barcelona October 11 – 14.

Ziccum CEO Ann Gidner: "Since my appointment in May we have constantly emphasized our commitment to building new strategic dialogues and relationships within the industry. Our unique ambient drying technology for vaccines and biologics is an enormously valuable technology. Together with our Chairman and Scientific Director I look forward to sharing our science and offering at these important industry events."

BOOK A MEETING ahead of the events with CEO Ann Gidner, Chairman Fredrik Sjövall or Scientific Director Fabrice Rose here:

Ann Gidner CEO - Mobile: +46 722 140 141
e-mail: gidner@ziccum.com

Fredrik Sjövall, Chairman - Mobile: +46 706 45 0875
e-mail: sjovall@ziccum.com

Fabrice Rose, Scientific Director: +46 709 802 520
e-mail: rose@ziccum.com

For more information about Ziccum, please contact:

Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141

Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75

Certified Adviser
Erik Penser Bank AB
Mail: certifiedadviser@penser.se
Phone: +46 8 463 83 00

About Ziccum

About Ziccum

Ziccum is developing new thermostable versions of vaccines and biologic materials for licensing to vaccine providers, developers, manufactures and CDMOs in the global pharmaceutical industry. Ziccum's patented drying technology, LaminarPace, is unique. It can dry-formulate temperature-sensitive vaccine materials at room temperature with high yields and low waste. These robust, thermostable dry powders could be stored and transported worldwide with no need for cold chain refrigeration or freezing. Ziccum is listed on the Nasdaq First North Growth Market

Attachments

[Ziccum on the move: company to attend major industry events across Europe in 2022](#)